Imfinzi (durvalumab)

pCPA File Number: 22289

Negotiation Status:

Concluded with an LOI

Indication(s):

Locally advanced or metastatic biliary tract cancer (BTC) in combination with gemcitabine-based chemotherapy

Sponsor/Manufacturer:

AstraZeneca Canada Inc.

CDA-AMC Project Number:

PC0296-000

pCPA Engagement Letter Issued:

2023-06-07

Negotiation Process Concluded:

2024-02-28